GlassScriptPhysician profile
John S Gentry
NPI 1871549691
$2,590.60
in general payments reported to CMS, 2019-2025
23 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $81.41 · 2021: $324 · 2022: $596 · 2023: $458 · 2024: $564 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,420 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,419.74 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $426.34 | 2021-2025 | Acthar |
| Bausch & Lomb Americas INC. | $330.23 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $329.17 | 2019-2025 | Rocklatan, Tryptyr, Eysuvis |
| Horizon Therapeutics Plc | $206.41 | 2020-2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $189.94 | 2022-2023 | Cequa |
| Aerie Pharmaceuticals, INC. | $166.60 | 2019-2021 | |
| Abbvie INC. | $110.55 | 2022 | |
| Oyster Point Pharma, INC. | $104.70 | 2022-2025 | Tyrvaya |
| Genentech USA, INC. | $102.01 | 2023-2025 | Vabysmo |
| Tarsus Pharmaceuticals, INC. | $91.85 | 2024-2025 | Xdemvy |
| Ocular Therapeutix, INC. | $89.00 | 2024 | Dextenza |
| Harrow Eye, LLC | $81.77 | 2023-2024 | Iheezo, Vevye |
| Vanda Pharmaceuticals INC. | $81.76 | 2021-2022 | |
| Sight Sciences, INC. | $53.23 | 2023-2024 | Omni Surgical System, Sion Surgical Instrument |
| Rxsight INC | $49.82 | 2024-2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $40.21 | 2019-2022 | |
| Lkc Technologies, INC. | $31.47 | 2025 | |
| Johnson & Johnson Surgical Vision, INC. | $22.22 | 2024 | Tecnis Iol |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $18.72 | 2025 | Austedo Xr |
| Dompe US, INC. | $18.43 | 2024 | Oxervate |
| Biotissue Holdings INC. | $14.03 | 2019 | |
| Eyepoint US, INC. | $12.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gentry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.